Efficacy of tirzepatide in glycemic control and weight management in adults with type 2 diabetes: a systematic review and meta-analysis of real-world studies.

Kamrul-Hasan ABM, Chatterjee S, Nagendra L, Dutta D, Pappachan JM

Postgraduate medical journal1 May 2026Cited by 1 (Europe PMC)

PMID41536268DOI10.1093/postmj/qgaf238PepBankPUB-41536268

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanSystematic reviewEfficacy outcome
In 13 real-world studies of adults with type 2 diabetes, tirzepatide was followed by a mean HbA1c reduction of 0.91%.
In plain wordsIn real-world studies of adults with type 2 diabetes, HbA1c fell by an average of 0.91% on tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change
Study
n = 89,296
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3-18 monthsAs given in this study (human).
Measurements
Mean HbA1c reduction
0.91%
13 real-world studies
Source sentences
Summary
13 real-world studies (N = 89 296; duration 3-18 months) with moderate to serious bias revealed a mean HbA1c reduction of 0.91% (95% confidence interval [CI]: -1.04 to -0.79)
Report a problemFND-4153626801
02HumanSystematic reviewEfficacy outcome
In 13 real-world studies of adults with type 2 diabetes, tirzepatide was followed by a weight loss of 9.7 kg.
In plain wordsIn real-world studies of adults with type 2 diabetes, average weight loss was 9.7 kg on tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseBody weight change
Study
n = 89,296
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3-18 monthsAs given in this study (human).
Measurements
Mean weight loss
9.7 kg
13 real-world studies
Source sentences
Summary
13 real-world studies (N = 89 296; duration 3-18 months) with moderate to serious bias revealed a mean HbA1c reduction of 0.91% (95% confidence interval [CI]: -1.04 to -0.79), weight loss of 9.7 kg (95% CI: -14.05 to -5.35), and body mass index decrease of 2.09 kg/m2 (95% CI: -3.27 to -0.92).
Report a problemFND-4153626802
03HumanSystematic reviewEfficacy outcome
In 13 real-world studies of adults with type 2 diabetes, tirzepatide was followed by a BMI decrease of 2.09 kg/m2.
In plain wordsIn real-world studies of adults with type 2 diabetes, BMI fell by an average of 2.09 kg/m2 on tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseBMI change
Study
n = 89,296
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3-18 monthsAs given in this study (human).
Measurements
Mean BMI decrease
2.09 kg/m2
13 real-world studies
Source sentences
Summary
13 real-world studies (N = 89 296; duration 3-18 months) with moderate to serious bias revealed a mean HbA1c reduction of 0.91% (95% confidence interval [CI]: -1.04 to -0.79), weight loss of 9.7 kg (95% CI: -14.05 to -5.35), and body mass index decrease of 2.09 kg/m2 (95% CI: -3.27 to -0.92).
Report a problemFND-4153626803
04HumanSystematic reviewEfficacy outcome
In real-world studies of adults with type 2 diabetes, 64% of tirzepatide users reached HbA1c below 7%.
In plain wordsIn real-world studies of adults with type 2 diabetes, 64% of people on tirzepatide reached HbA1c below 7%.
Peptide
Tirzepatide
Outcome
Not applicableProportion reaching HbA1c below 7%
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3-18 monthsAs given in this study (human).
Measurements
Reached HbA1c <7%
64%
tirzepatide users
Source sentences
Summary
Overall, 64% of tirzepatide users reached HbA1c <7%.
1 context sentence(design, population, supporting numbers)
Summary · context
13 real-world studies (N = 89 296; duration 3-18 months) with moderate to serious bias revealed a mean HbA1c reduction of 0.91% (95% confidence interval [CI]: -1.04 to -0.79), weight loss of 9.7 kg (95% CI: -14.05 to -5.35), and body mass index decrease of 2.09 kg/m2 (95% CI: -3.27 to -0.92).
Report a problemFND-4153626804
05HumanSystematic reviewEfficacy outcome
In real-world studies of adults with type 2 diabetes, tirzepatide lowered HbA1c more than the control (mean difference -0.38%).
In plain wordsIn real-world studies of adults with type 2 diabetes, tirzepatide lowered HbA1c more than the control treatment.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c difference versus control
Study
n: not reported in source
Comparator
Control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3-18 monthsAs given in this study (human).
Measurements
HbA1c mean difference
−0.38%
tirzepatide vs control
Source sentences
Summary
Furthermore, tirzepatide lowered HbA1c (mean difference [MD] -0.38%; 95% CI: -0.44 to -0.33)
1 context sentence(design, population, supporting numbers)
Summary · context
13 real-world studies (N = 89 296; duration 3-18 months) with moderate to serious bias revealed a mean HbA1c reduction of 0.91% (95% confidence interval [CI]: -1.04 to -0.79), weight loss of 9.7 kg (95% CI: -14.05 to -5.35), and body mass index decrease of 2.09 kg/m2 (95% CI: -3.27 to -0.92).
Report a problemFND-4153626805
06HumanSystematic reviewEfficacy outcome
In real-world studies of adults with type 2 diabetes, tirzepatide lowered body weight more than the control (mean difference -6.27 kg).
In plain wordsIn real-world studies of adults with type 2 diabetes, tirzepatide lowered body weight more than the control treatment.
Peptide
Tirzepatide
Outcome
DecreaseBody weight difference versus control
Study
n: not reported in source
Comparator
Control
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3-18 monthsAs given in this study (human).
Measurements
Body weight mean difference
−6.27 kg
tirzepatide vs control
Source sentences
Summary
and body weight (MD -6.27 kg; 95% CI: -9.22 to -0.33) more than the control.
1 context sentence(design, population, supporting numbers)
Summary · context
13 real-world studies (N = 89 296; duration 3-18 months) with moderate to serious bias revealed a mean HbA1c reduction of 0.91% (95% confidence interval [CI]: -1.04 to -0.79), weight loss of 9.7 kg (95% CI: -14.05 to -5.35), and body mass index decrease of 2.09 kg/m2 (95% CI: -3.27 to -0.92).
Report a problemFND-4153626806
07HumanSystematic reviewEfficacy outcome
In real-world studies of adults with type 2 diabetes, 47% of tirzepatide users lost at least 5% of baseline weight.
In plain wordsIn real-world studies of adults with type 2 diabetes, 47% of people on tirzepatide lost at least 5% of their weight.
Peptide
Tirzepatide
Outcome
DecreaseProportion losing at least 5% of baseline weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3-18 monthsAs given in this study (human).
Measurements
Responders ≥5% weight loss
47%
tirzepatide users
Source sentences
Summary
47%, 23%, 9%, and 4% of tirzepatide users lost ≥5%, ≥10%, ≥15%, and ≥ 20% of their baseline weight, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
13 real-world studies (N = 89 296; duration 3-18 months) with moderate to serious bias revealed a mean HbA1c reduction of 0.91% (95% confidence interval [CI]: -1.04 to -0.79), weight loss of 9.7 kg (95% CI: -14.05 to -5.35), and body mass index decrease of 2.09 kg/m2 (95% CI: -3.27 to -0.92).
Report a problemFND-4153626807
08HumanSystematic reviewEfficacy outcome
In real-world studies of adults with type 2 diabetes, 23% of tirzepatide users lost at least 10% of baseline weight.
In plain wordsIn real-world studies of adults with type 2 diabetes, 23% of people on tirzepatide lost at least 10% of their weight.
Peptide
Tirzepatide
Outcome
DecreaseProportion losing at least 10% of baseline weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3-18 monthsAs given in this study (human).
Measurements
Responders ≥10% weight loss
23%
tirzepatide users
Source sentences
Summary
47%, 23%, 9%, and 4% of tirzepatide users lost ≥5%, ≥10%, ≥15%, and ≥ 20% of their baseline weight, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
13 real-world studies (N = 89 296; duration 3-18 months) with moderate to serious bias revealed a mean HbA1c reduction of 0.91% (95% confidence interval [CI]: -1.04 to -0.79), weight loss of 9.7 kg (95% CI: -14.05 to -5.35), and body mass index decrease of 2.09 kg/m2 (95% CI: -3.27 to -0.92).
Report a problemFND-4153626808
09HumanSystematic reviewEfficacy outcome
In real-world studies of adults with type 2 diabetes, 9% of tirzepatide users lost at least 15% of baseline weight.
In plain wordsIn real-world studies of adults with type 2 diabetes, 9% of people on tirzepatide lost at least 15% of their weight.
Peptide
Tirzepatide
Outcome
DecreaseProportion losing at least 15% of baseline weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3-18 monthsAs given in this study (human).
Measurements
Responders ≥15% weight loss
9%
tirzepatide users
Source sentences
Summary
47%, 23%, 9%, and 4% of tirzepatide users lost ≥5%, ≥10%, ≥15%, and ≥ 20% of their baseline weight, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
13 real-world studies (N = 89 296; duration 3-18 months) with moderate to serious bias revealed a mean HbA1c reduction of 0.91% (95% confidence interval [CI]: -1.04 to -0.79), weight loss of 9.7 kg (95% CI: -14.05 to -5.35), and body mass index decrease of 2.09 kg/m2 (95% CI: -3.27 to -0.92).
Report a problemFND-4153626809
10HumanSystematic reviewEfficacy outcome
In real-world studies of adults with type 2 diabetes, 4% of tirzepatide users lost at least 20% of baseline weight.
In plain wordsIn real-world studies of adults with type 2 diabetes, 4% of people on tirzepatide lost at least 20% of their weight.
Peptide
Tirzepatide
Outcome
DecreaseProportion losing at least 20% of baseline weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3-18 monthsAs given in this study (human).
Measurements
Responders ≥20% weight loss
4%
tirzepatide users
Source sentences
Summary
47%, 23%, 9%, and 4% of tirzepatide users lost ≥5%, ≥10%, ≥15%, and ≥ 20% of their baseline weight, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
13 real-world studies (N = 89 296; duration 3-18 months) with moderate to serious bias revealed a mean HbA1c reduction of 0.91% (95% confidence interval [CI]: -1.04 to -0.79), weight loss of 9.7 kg (95% CI: -14.05 to -5.35), and body mass index decrease of 2.09 kg/m2 (95% CI: -3.27 to -0.92).
Report a problemFND-4153626810

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.